ProQR Therapeutics (PRQR) Free Cash Flow (2013 - 2026)

ProQR Therapeutics (PRQR) has reported Free Cash Flow for 14 consecutive years, with -$13.2 million the latest figure, recorded in Q1 2026.

• Quarterly Free Cash Flow rose 29.95% year-over-year to -$13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59.6 million (down 19.55% YoY) and the FY2025 annual result came in at -$63.3 million, down 37.34% from the prior year.
• Free Cash Flow advanced to -$13.2 million in Q1 2026 per PRQR's latest filing, from -$19.0 million in the prior quarter.
• Over the last five years, Free Cash Flow for PRQR reached as high as $50.8 million in Q1 2023 and fell as low as -$23.6 million in Q1 2022.
• A 5-year average of -$10.7 million and a median of -$13.7 million in 2025 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow sank 521.76% — and 2023, when it soared 315.74%.
• Year by year, Free Cash Flow stood at -$21.9 million in 2022, then surged by 70.35% to -$6.5 million in 2023, then sank by 157.86% to -$16.8 million in 2024, then slipped by 13.16% to -$19.0 million in 2025, then soared by 30.23% to -$13.2 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$13.2 million, -$19.0 million, and -$13.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.